News

FDA greenlights Roche's Actemra
Enlarge image

BusinessSwitzerland

FDA greenlights Roche's Actemra

02.05.2013 - Hoffmann La-Roche’s US subsidiary Genentech has gained approval for its IL-6-R blocking arthritis antibody Actemra in children.

Tocilizumab is now authorised for marketing in the US as a treatment of polyarticular juvenile idiopathic arthritis (PJIA). The medicine can be used in children two years of age and older with active disease as a monotherapy or in combination with methotrexate. 

Polyarticular juvenile idiopathic arthritis affects approximately 30 in every 100,000 children. The chronic disease is characterised by inflammation in five or more joints within the first six months of the disease and most commonly affects the small joints in the body such as the hands and feet. 

The label extension of Roche’s Interleukin-6 receptor antagonist is based on data from the combined open label/double blind Phase III CHERISH study. A total of 91% of patients taking the humanised monoclonal antibody plus methotrexate and 83% of those taking tocilizumab alone achieved an ACR 30 response at week 16 compared to baseline. In the randomized double-blind placebo-controlled withdrawal phase of the trial, 26% of patients in the Actemra arm experienced disease flares compared to 48% in the placebo arm. 

Infections, which were in part fatal, were the most common serious adverse events over 40 weeks. Other serious side effects include perforation of the stomach and intestines, changes in blood test results (including low white blood cell count, low platelet count, increase in certain liver function tests, and increase in blood cholesterol levels), hepatitis B infection becoming an active infection again, and nervous system problems. Actemra affects the immune system and may increase a patient's risk of certain cancers.  

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/roche-gets-green-light-for-il-6-r-blocker.html

EU

04.09.2015 Crowdfinancing has just recently emerged as a financing instrument in the Life Sciences. A new report lists 42 European companies in the sector that have raised a total of almost €23m.

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOLVA (CH)1.49 CHF12.03%
  • TIGENIX (B)1.23 EUR9.82%
  • OREXO (S)49.10 SEK8.39%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-11.67%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • PROTHENA PLC (IE)52.70 USD-6.54%

TOP

  • KARO BIO (S)41.90 SEK2568.8%
  • BIOTECH PHARMACON (N)16.80 NOK80.6%
  • TRANSGENE (F)4.86 EUR75.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-49.6%
  • THROMBOGENICS (B)2.85 EUR-42.1%

TOP

  • KARO BIO (S)41.90 SEK4661.4%
  • ADOCIA (F)89.30 EUR409.1%
  • GALAPAGOS (B)53.25 EUR325.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)11.35 SEK-81.7%
  • BIOTEST (D)20.30 EUR-76.5%

No liability assumed, Date: 03.09.2015